Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 2/20 | 0.52 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.45 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.43 |
| ▸ | METTL14 | Q9HCE5 | 1/20 | 0.43 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22434979 | 1.00 | ADK (0.52) | ADKP2RY12METTL3METTL14SLC29A1 | |
| SCHEMBL31123791 | 0.85 | ADK (0.72) | ADKMETTL3METTL14SLC29A1ADORA3 | |
| SCHEMBL24687181 | 0.85 | ADK (0.72) | ADKMETTL3METTL14SLC29A1ADORA3 | |
| SCHEMBL23023836 | 0.85 | ADK (0.72) | ADKMETTL3METTL14SLC29A1ADORA3 | |
| SCHEMBL25410585 | 0.83 | ADK (0.60) | ADKMETTL3METTL14SLC29A1 | |
| SCHEMBL31167393 | 0.83 | ADK (0.60) | ADKMETTL3METTL14SLC29A1 | |
| SCHEMBL19344245 | 0.82 | ADK (0.41) | ADKADORA1ADORA3ADORA2A | |
| SCHEMBL14644657 | 0.81 | ADK (0.47) | ADKMETTL3METTL14SLC29A1 | |
| SCHEMBL29313467 | 0.81 | ADK (0.53) | ADKMETTL3METTL14SLC29A1ADORA1 | |
| SCHEMBL29313461 | 0.80 | ADK (0.60) | ADKMETTL3METTL14SLC29A1ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200289539-A1 | NOVEL SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200289539-A1 | NOVEL SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | ADK 284/4885P2RY12 2055/4885METTL3 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.